Compare ATEC & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEC | ABCL |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2006 | 2020 |
| Metric | ATEC | ABCL |
|---|---|---|
| Price | $8.24 | $5.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $22.00 | $8.40 |
| AVG Volume (30 Days) | 4.6M | ★ 8.8M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.04 | 10.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $101,739,000.00 | $75,128,000.00 |
| Revenue This Year | $18.97 | N/A |
| Revenue Next Year | $16.70 | $21.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $6.82 | $1.97 |
| 52 Week High | $23.29 | $6.52 |
| Indicator | ATEC | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 42.18 | 64.05 |
| Support Level | $6.82 | $3.32 |
| Resistance Level | $16.58 | $5.63 |
| Average True Range (ATR) | 0.52 | 0.45 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 38.04 | 73.67 |
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.